(Q37827364)

23 August 2017

1 reference

title

Resistance to inhibitors of the human immunodeficiency virus type 1 integration (English)

1 reference

23 August 2017

Daria J Hazuda

1

1 reference

23 August 2017

publication date

1 September 2010

1 reference

The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases

23 August 2017

published in

1 reference

23 August 2017

volume

14

1 reference

23 August 2017

issue

5

1 reference

23 August 2017

page(s)

513-518

1 reference

Raltegravir: a new antiretroviral class for salvage therapy

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970103-3

7 January 2021

Structure and function of HIV-1 integrase

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970103-3

7 January 2021

HIV integrase, a brief overview from chemistry to therapeutics

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970103-3

7 January 2021

HIV-1 DNA integration: Mechanism of viral DNA cleavage and DNA strand transfer

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970103-3

7 January 2021

HIV-1 integrase inhibitors: a decade of research and two drugs in clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970103-3

7 January 2021

Integrase inhibitors to treat HIV/AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970103-3

7 January 2021

Human immunodeficiency virus type 1 integrase: effects of mutations on viral ability to integrate, direct viral gene expression from unintegrated viral DNA templates, and sustain viral propagation in primary cells

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970103-3

7 January 2021

Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970103-3

7 January 2021

HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects.

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970103-3

7 January 2021

HIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integrase

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970103-3

7 January 2021

Diketo acid inhibitor mechanism and HIV-1 integrase: implications for metal binding in the active site of phosphotransferase enzymes

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970103-3

7 January 2021

Retroviral intasome assembly and inhibition of DNA strand transfer

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970103-3

7 January 2021

Crystal structures of the catalytic domain of HIV-1 integrase free and complexed with its metal cofactor: high level of similarity of the active site with other viral integrases

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970103-3

7 January 2021

Virological and immunological response to HAART regimen containing integrase inhibitors in HIV-2-infected patients

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970103-3

7 January 2021

Raltegravir treatment response in an HIV-2 infected patient: a case report

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970103-3

7 January 2021

Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137)

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970103-3

7 January 2021

Raltegravir and etravirine are active against HIV type 1 group O.

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970103-3

7 January 2021

Raltegravir is a potent inhibitor of XMRV, a virus implicated in prostate cancer and chronic fatigue syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970103-3

7 January 2021

Analysis of natural sequence variation and covariation in human immunodeficiency virus type 1 integrase

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970103-3

7 January 2021

Natural polymorphisms of human immunodeficiency virus type 1 integrase and inherent susceptibilities to a panel of integrase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970103-3

7 January 2021

Clade-specific HIV-1 integrase polymorphisms do not reduce raltegravir and elvitegravir phenotypic susceptibility

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970103-3

7 January 2021

A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970103-3

7 January 2021

Resistance mutations in human immunodeficiency virus type 1 integrase selected with elvitegravir confer reduced susceptibility to a wide range of integrase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970103-3

7 January 2021

Comparison of raltegravir and elvitegravir on HIV-1 integrase catalytic reactions and on a series of drug-resistant integrase mutants

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970103-3

7 January 2021

Development of resistance against diketo derivatives of human immunodeficiency virus type 1 by progressive accumulation of integrase mutations

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970103-3

7 January 2021

Multiple mutations in human immunodeficiency virus-1 integrase confer resistance to the clinical trial drug S-1360.

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970103-3

7 January 2021

The naphthyridinone GSK364735 is a novel, potent human immunodeficiency virus type 1 integrase inhibitor and antiretroviral

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970103-3

7 January 2021

Mutations in human immunodeficiency virus type 1 integrase confer resistance to the naphthyridine L-870,810 and cross-resistance to the clinical trial drug GS-9137.

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970103-3

7 January 2021

Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970103-3

7 January 2021

Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970103-3

7 January 2021

Drug resistance profiles for the HIV integrase gene in patients failing raltegravir salvage therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970103-3

7 January 2021

Loss of raltegravir susceptibility by human immunodeficiency virus type 1 is conferred via multiple nonoverlapping genetic pathways

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970103-3

7 January 2021

Evolution of integrase resistance during failure of integrase inhibitor-based antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970103-3

7 January 2021

Selective-advantage profile of human immunodeficiency virus type 1 integrase mutants explains in vivo evolution of raltegravir resistance genotypes.

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970103-3

7 January 2021

The dynamics of appearance and disappearance of HIV-1 integrase mutations during and after withdrawal of raltegravir therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970103-3

7 January 2021

Integrase variability and susceptibility to HIV integrase inhibitors: impact of subtypes, antiretroviral experience and duration of HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS1413-8670%2810%2970103-3

7 January 2021

10.1016/S1413-8670(10)70103-3

Identifiers

DOI

1 reference

23 August 2017

1 reference